Skip to main content

Table 2 In vitro cytotoxicity of ACT-101 Conjugates with different maytansinoid toxins

From: High anti-tumor activity of a novel alpha-fetoprotein-maytansinoid conjugate targeting alpha-fetoprotein receptors in colorectal cancer xenograft model

Sample

DPR

U-937

COLO-205

n

AVG ± SD (nM)

n

AVG ± SD (nM)

ACT-101-DM4

4.1

2

3.20 ± 0.64

2

8.51 + 0.98

ACT-101DM1

4.0

3

6.09 ± 0.13

3

7.77 ± 3.47

ACT-101-ABZ982

4.0

3

13.52 ± 2.45

3

38.58 ± 4.30

DM4

N/A

2

2.22 ± 0.41

2

1.29 ± 0.68

DM1

N/A

3

2.74 ± 0.72

3

5.42 ± 0.59

ABZ981

N/A

3

3.28 ± 0.60

3

3.92 ± 0.26

  1. DPR Drug to Protein Ratio; DM4, DM1, ABZ981—maytansinoids alone; AVG ± SD: Average concentration in nM ± Standard Deviation
Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us